S-1/A: Adagio Medical Holdings Files Amendment to S-1 Registration for Share Resale

Adagio Medical Holdings updates its S-1 registration statement to facilitate the resale of up to 67,963,695 shares of common stock by selling stockholders.

Summary

• Adagio Medical Holdings has filed a pre-effective amendment to its existing S-1 registration statement to update the Executive Compensation section, reflecting compensation paid in the fiscal year ended December 31, 2024.
• No additional securities are being registered under this amendment.
• The prospectus covers the offer, sale, or other disposition of up to 67,963,695 shares of common stock by selling stockholders.
• These shares include PIPE Shares, Pre-Funded Warrant Shares, PIPE Warrant Shares, Convertible Note Shares, Convert Warrant Shares, shares issued to the Sponsor, shares issued to affiliates and Independent ARYA Directors, and shares issuable upon exercise of stock options.
• The selling stockholders may offer these shares publicly or through private transactions at prevailing market prices or negotiated prices.
• Adagio Medical Holdings will not receive any proceeds from the sale of these shares, except for amounts received upon the cash exercise of warrants.
• The company believes the likelihood that warrant holders will exercise their warrants for cash is dependent on the trading price of their common stock.
• The company will bear all costs associated with the registration of these securities.
• The selling stockholders will bear all commissions and discounts related to their sale of shares.
• Approximately 82% of ARYA's Class A ordinary shares were redeemed for cash at approximately $11.56 per share in connection with the Business Combination.
• The shares being offered represent a substantial percentage of the total outstanding shares of Common Stock.
• The sale of these securities, or the perception of potential sales, could significantly decrease the public trading price of the company's securities.
• Lock-up restrictions entered into in connection with the Business Combination will expire on January 31, 2025, potentially leading to sales by executive officers and Independent ARYA Directors.
• Despite a decline in the stock price, some selling stockholders may still profit due to lower purchase prices.
• Based on a Common Stock price of $1.24 as of February 3, 2025, PIPE Investors, Convert Investors, the Sponsor, Independent ARYA Directors, and the Chief Operating Officer may experience potential losses or profits depending on their initial purchase prices.
• The company's Common Stock is listed on The Nasdaq Capital Market under the symbol ADGM.
• Adagio Medical Holdings is an emerging growth company and has elected to comply with reduced public company reporting requirements.

Sentiment

Score: 4

Explanation: The document is largely factual and descriptive, but the potential for share price decline and losses for investors tempers the sentiment.

Positives

• The company will bear all costs, expenses and fees in connection with the registration of these securities, including with regard to compliance with state securities or blue sky laws.

Negatives

• The sale of a significant number of shares of Common Stock issuable upon the exercise of the Warrants and upon conversion of the Convert Notes could result in a significant decline in the public trading price of the company's securities.
• The frequency of such sales could also cause the market price of the company's securities to decline or increase the volatility in the market price of the company's securities.
• Despite a significant decline in the public trading price of our Common Stock, the selling stockholders may still experience a positive rate of return on the securities they purchased due to the differences in the purchase prices described above and the public trading price of our securities.

Risks

• The sale of shares by the selling stockholders, or the perception that these sales could occur, could cause the market price of the Common Stock to decline significantly.
• The future exercise of registration rights may adversely affect the market price of the Common Stock.
• The Perceptive PIPE Investor has control over key decision making as a result of its control of a majority of the voting power of our outstanding Common Stock.
• Our stock price may be volatile and may decline regardless of its operating performance.
• We may be unable to maintain the listing of our securities on Nasdaq in the future.
• Future sales of shares by existing stockholders could cause our stock price to decline.
• We may issue additional shares of common stock or other equity securities without your approval, which would dilute your ownership interests and may depress the market price of our common stock.
• We have identified material weaknesses in our internal controls over financial reporting. If we are unable to remediate these material weaknesses, if management identifies additional material weaknesses in the future or if we otherwise fail to maintain effective internal controls over financial reporting, we may not be able to accurately or timely report our financial position or results of operations, which may adversely affect our business and stock price or cause our access to the capital markets to be impaired.

Future Outlook

The company believes the likelihood that warrant holders will exercise their warrants for cash is dependent on the trading price of their common stock.

Industry Context

The document relates to the financial activities of a medical device company in the electrophysiology field, which is intensely competitive and subject to rapid change. Competitors include Medtronic, Boston Scientific, Abbott and Johnson & Johnson.

Comparison to Industry Standards

• The document mentions that in PsAF patients in the first-in-human CRYOSURE-2 trial, such favorable outcomes include 85% freedom from AF in patients after a single ULTC procedure (versus 51%-65% reported for other catheter technologies) and 98.5% of subjects in the device cryomapping cohort did not experience device-related complications.
• The document mentions that in VT patients in the first-in-human CRYOCURE-VT trial, such favorable outcomes include a 0% rate of major adverse events (versus 11.5% significant complications, including deaths, reported for VT ablation procedures using other catheter technologies), 94% acute procedural success, 60% freedom from sustained VT and 81% freedom from implantable cardioverter defibrillator shock at six months.

Stakeholder Impact

• The sale of shares by the selling stockholders, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future and at a price that we deem appropriate.

Next Steps

• The selling stockholders will determine when and how they will dispose of the shares of Common Stock registered for resale under this prospectus.

Key Dates

Keywords

common stock, registration statement, selling stockholders, securities, warrants, convertible notes, business combination, Adagio Medical Holdings, PIPE, shares